INSULET CORP

Insulet Corporation is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Classic Omnipod. The company estimates that approximately 6 million people have type 1 diabetes in the countries it currently serves, and approximately 6 million people have insulin-requiring type 2 diabetes in those countries, with another 3 million people with type 2 diabetes in the United States requiring only basal insulin. Management estimates that approximately 40% of the type 1 diabetes population in the United States and 25% of the international type 1 diabetes population use insulin pump therapy, with an even smaller portion of the insulin-requiring type 2 diabetes population using pump therapy, indicating a significant available market for the Omnipod platform globally.

The diabetes medical device market is highly competitive, subject to rapid change, and significantly affected by new product introductions. The Omnipod platform competes for consumers in the insulin delivery market, primarily against companies that provide products and supplies for multiple daily injection therapy, including smart pens, as most new Omnipod users come from MDI therapy. The company also competes with companies in the insulin pump market, including tubed pump companies such as Medtronic Diabetes and Tandem Diabetes Care Inc., as well as emerging companies like Beta Bionics Inc., and companies working to develop new insulin patch pumps. Management believes the Omnipod platform's innovative proprietary design and differentiated features allow people with insulin-dependent diabetes to manage their diabetes with unprecedented freedom, comfort, convenience, and ease.

The company generates most of its revenue from sales of its Omnipod products, which feature a small, lightweight, self-adhesive disposable tubeless Pod that the user fills with insulin and wears directly on the body for up to three days at a time. The unique patented design allows the company to provide Pod therapy at a relatively low or no up-front investment, and as the customer base grows, an increasing portion of revenues is expected to come from recurring sales of the disposable Pods. The company sells Omnipod products to wholesalers that supply the pharmacy channel in the United States, and through distribution partners and directly to consumers internationally, with 86% of Omnipod product sales globally being through intermediaries for the year ended December 31, 2025.

The Omnipod platform includes Omnipod 5, which builds on the Omnipod DASH platform and is a tubeless automated insulin delivery system that integrates with a continuous glucose monitor to manage blood sugar and is fully controlled by a compatible personal smartphone or Omnipod 5 Controller. Omnipod 5 includes a proprietary AID algorithm embedded in the Pod that utilizes glucose values from a third-party CGM to predict glucose levels and automatically adjusts insulin dosing, and it is currently available in 19 countries. In August 2024, the company received FDA clearance for an expanded indication of Omnipod 5 for people with type 2 diabetes (ages 18 years and older) in the United States. The Pod currently integrates with Dexcom's G6 and G7 CGMs and with Abbott's FreeStyle Libre 2 Plus sensor in various markets. Omnipod DASH features a secure wireless Bluetooth enabled Pod controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface, providing continuous insulin delivery at preset rates. Following the launch of Omnipod 5, the vast majority of the customer base is no longer using the Classic Omnipod product, and the company is phasing it out.

The company's non-insulin Drug Delivery product line involves the development, manufacture, and sale of a modified Pod for delivery of a specific drug other than insulin, with substantially all of its commercialized Drug Delivery revenue consisting of sales of a customized version of its product for use in Amgen's Neulasta Onpro kit under an agreement that expires in December 2028. Drug Delivery revenue was $34.1 million ¹ and $38.9 million ² in 2025 and 2024, respectively.

In 2025, the company launched Omnipod 5 in nine additional countries, completed the randomized portion of its RADIANT study in France, the United Kingdom, and Belgium, and completed STRIVE, its pivotal study for the next generation hybrid closed loop system. The company also finished enrollment for EVOLUTION 2, its safety and feasibility study for a fully closed loop AID system for type 2 diabetes, and received 510(k) clearance for enhancements to the Omnipod 5 algorithm to include a lower target glucose set point. In March 2025, the company issued $450 million ³ aggregate principal amount of 6.5% senior unsecured notes due 2033, and during 2025 repurchased $419.9 million ⁴ aggregate principal amount of its Convertible Senior Notes for $541.5 million ⁵ in cash, resulting in a $123.9 million ⁶ loss on extinguishment. The company also repurchased approximately 184 thousand ⁷ shares for $59.6 million ⁸ under a share repurchase program authorized in March 2025.

Total revenue increased $636.6 million ⁹, or 30.7% ¹⁰, to $2,708.1 million ¹¹ in 2025, compared with $2,071.6 million ¹² in 2024. Gross margin was 71.6% ¹³ in 2025, compared with 69.8% ¹⁴ in 2024. Operating income was $473.8 million ¹⁵ in 2025, compared with $308.9 million ¹⁶ in 2024. Net income was $247.1 million ¹⁷ in 2025, compared with $418.3 million ¹⁸ in 2024. Adjusted EBITDA was $645.5 million ¹⁹ in 2025, compared with $457.2 million ²⁰ in 2024.

A key growth vector is the continued international expansion of Omnipod 5, which is currently available in 19 countries and was launched in nine additional countries in 2025, with further launches in several countries in the Middle East in early 2026. The company expects international sales to contribute significantly to future growth, as international sales made up 28% ²¹ of revenues in 2025. Another major growth vector is the expansion into the insulin-requiring type 2 diabetes market, following the FDA clearance for an expanded indication of Omnipod 5 for people with type 2 diabetes in August 2024, and the company made a strategic decision to drive growth in the type 2 diabetes market with Omnipod 5, deciding not to move forward with the commercialization of Omnipod GO.

The company expects net interest expense to increase to $40 million ²² or more in 2026, primarily due to lower interest income. The company does not expect tariffs to have a significant impact on its gross margin in 2026, but notes that should the exemption currently in place for certain medical devices be eliminated, tariffs would have a material impact on results of operations in future years.

The company continues to take steps to strengthen its global manufacturing capabilities, having begun producing product at its new manufacturing plant in Malaysia in 2024 and investing in another manufacturing plant in Costa Rica to support continued growth. The company expects capital expenditures for 2026 to increase compared with 2025 as it continues to expand globally and optimize its manufacturing and supply chain operations.

Research and development expenses were $301.1 million ²³ in 2025, compared with $219.6 million ²⁴ in 2024. Capital expenditures were $191.6 million ²⁵ in 2025, compared with $124.9 million ²⁶ in 2024. In March 2025, the Board of Directors authorized a program to repurchase up to $125.0 million ²⁷ of common stock through December 31, 2026 to offset dilution from stock-based compensation, and in February 2026, the Board extended the authorization through December 31, 2027 and approved an additional $350 million ²⁸ in repurchases of common stock, with plans to utilize $300 million ²⁹ of existing cash to repurchase shares in the first quarter of 2026. The company does not anticipate paying any cash dividends for the foreseeable future.

The company faces structural headwinds from the increasing use of GLP-1 products that may delay the progression of type 2 diabetes in obese patients, which could reduce the potential market for its products. Additionally, the company is exposed to risks from the continuing worldwide macroeconomic and geopolitical uncertainty, including inflation, rising interest rates, and reduced availability of capital markets, which could adversely affect its business and prospects.

The company faces constraints from the implementation of more restrictive trade policies, such as higher tariffs or new barriers to entry, which could negatively impact its business, results of operations, and financial condition. The U.S. Department of Commerce Bureau of Industry and Security has announced an investigation under Section 232 of the Trade Expansion Act of 1962 into imports of medical devices such as insulin pumps, which could result in overriding the tariff exemption currently in place for certain medical devices and have a material impact on results of operations in future years.

The company currently relies on sales of its Omnipod product platform to generate most of its revenue, and failure to successfully market and sell these products or to retain and grow its customer base would have a negative impact on business, revenue, financial condition, and results of operations. The company faces intense competition from established insulin pump manufacturers like Medtronic Diabetes and Tandem Diabetes Care Inc., as well as from MDI therapy and emerging technologies, and if competitors develop superior products or lower prices, the company could experience pricing pressure and decreased revenue. The company is dependent on third-party suppliers for components, including sole-sourced components like application-specific integrated circuit chips and Bluetooth low-energy chips, and any interruption or inability to obtain these components could hinder manufacturing. The company's international operations subject it to risks including trade protection measures such as tariff increases, and the U.S. Department of Commerce has initiated a Section 232 investigation into imports of medical devices that could result in the elimination of the current tariff exemption for certain medical devices, which would have a material impact on results of operations. The company's agreement with Amgen for its Drug Delivery product line expires in December 2028 ³⁰, and if this agreement is terminated or not renewed, financial results could be negatively impacted.

Management's message emphasizes the company's mission to transform the lives of people with diabetes and its financial objective to sustain profitable growth. Key strategic priorities include continuing to launch Omnipod 5 in new international markets, driving growth in the type 2 diabetes market with Omnipod 5, and advancing product development efforts including the integration of Omnipod 5 with Abbott's FreeStyle Libre 3 Plus, developing Omnipod 6 as the next-generation AID product, and developing a fully closed loop AID system for type 2 diabetes. Management also highlights the completion of the STRIVE pivotal study for the next generation hybrid closed loop system and the completion of enrollment for the EVOLUTION 2 safety and feasibility study for a fully closed loop AID system for type 2 diabetes, with plans to start the U.S. IDE pivotal study in 2026.